MedTrace Logo

Vismodegib on Locally Advanced Basal Cell Carcinoma Under Real World Conditions

NCT02781389 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 53

Last updated 2021-06-03

No results posted yet for this study

Summary

The aim of this non-interventional study is to provide further data on the utilization, effectiveness, safety and clinical benefit including duration of response of Vismodegib for treatment of locally advanced basal cell carcinoma (laBCC), inappropriate for surgery or radiotherapy under real world clinical conditions.

Conditions

Sponsors & Collaborators

  • OnkoDataMed GmbH

    collaborator INDUSTRY

  • University Hospital, Essen

    lead OTHER

Principal Investigators

  • Dirk Schadendorf, Professor · Universitätsklinikum Essen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-29
Primary Completion
2021-05-31
Completion
2021-05-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02781389 on ClinicalTrials.gov